STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety

A child died in a Chinese gene-editing trial for Duchenne muscular dystrophy conducted by HuidaGene, reigniting concerns about transparency and safety in such trials. The company presented initial data at a U.S. conference but later became unresponsive, with its CEO and CTO departing, and the study was recently declared complete without clear details on patient outcomes.